Kaynakça
Curtis BR. Drug-induced immune thrombocytopenia: incidence, clinical features, laboratory testing, and pathogenic mechanisms. Immunohematology. 2014;30:55-65.
Erol S. Rifampisin. Güncel Bilgiler Işıgında Antibiyotikler. Ed: Leblebicioğlu H, Usluer G, Ulusoy S. Bilimsel Tıp Kitapevi, 2008.
Tanrıkulu AÇ, Abakay A, Turan H. Tanrıkulu AÇ, Abakay A, Turan H. Rifampicin induced trombocyttopenia: A case report. Göztepe Tıp Dergisi. 2010;25:142-4.
Poole G, Stradling P, Worlledge S. Potentially serious side-effects of highdose twice-weekly rifampicin. Postgrad Med J. 1971;47:727-47.
Di Berardino L, Perna G, Silvestri LG. Antibodies against rifampicin in patients with tuberculosis after discontinuation of daily treatment. Am Rev Respir Dis. 1976;114:1189-90.
Burgess JK, Lopez JA, Gaudry LE, Chong BH. Rifampicin-dependent antibodies bind a similar or identical epitope to glycoprotein IX-specific quinine-dependent antibodies. Blood. 2000;95:1988-92.
Pereira J, Hidalgo P, Ocqueteau M, Blacutt M, Marchesse M, Nien Y, Letelier L, Mezzano D. Glycoprotein Ib/IX complex is the target in rifampicininduced immune thrombocytopenia. Br J Haematol. 2000;110:907-10.
Wazny LD, Ariano RE. Evaluation and management of drug induced thrombocytopenia in the acutely ill patients. Pharmacotherapy. 2000;20:292-307.
Bansal R, Sharma PK, Sharma A. A case of thrombocytopenia caused by rifampicin and pyrazinamide. Indian J Pharmacol. 2013;45:405-7.
